Cure8 research brief
People with IBD on biologics or small molecules who live in or travel to areas where Coccidioides is endemic face a measurable risk of coccidioidomycosis. How the infection is classified (proven/probable/possible) influenced whether antifungal treatment was given and whether advanced IBD therapy was modified.
Adult patients with IBD (especially those on biologics or JAK inhibitors), clinicians managing IBD in endemic regions, and patients-on-biologics considering travel to endemic areas.
The study found that proven or probable infections prompted antifungal therapy and more frequent modification or interruption of advanced IBD drugs, whereas many patients with possible or nondiagnostic serology remained on therapy without major IBD complications. Antifungal courses were often prolonged.
Tumor necrosis factor alpha inhibitors were the class most commonly interrupted or stopped. Hospitalizations related to coccidioidomycosis occurred only in proven/probable cases.
Clinical context: For people with IBD living in or receiving care in Coccidioides-endemic regions, this study highlights the diagnostic categories clinicians use and the trade-offs involved in continuing versus pausing immunosuppressive therapies when infection is suspected.
Decisions appeared to be individualized based on diagnostic certainty and clinical severity.
This entry is based on the article abstract (retrospective observational cohort) from a tertiary care center in an endemic region. As an observational study, it describes associations and management patterns rather than proving causal effects. Local epidemiology and individual clinical judgment will influence management decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...
Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...
